These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27040168)

  • 21. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
    Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
    J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature.
    Hudesman D; Lichtiger S; Sands B
    Inflamm Bowel Dis; 2013 Mar; 19(3):644-9. PubMed ID: 23314243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel biologics in inflammatory bowel disease.
    Papachristou GI; Plevy S
    Gastroenterol Clin North Am; 2004 Jun; 33(2):251-69, ix. PubMed ID: 15177537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of inflammatory immunologic disease 2. Anti-cytokine therapies in inflammatory bowel disease.
    Matsumoto T
    Intern Med; 2007; 46(16):1307-9. PubMed ID: 17704612
    [No Abstract]   [Full Text] [Related]  

  • 25. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [1/2 The anti-TNF alpha drugs].
    Medjoub M; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Oct; (719):59-61. PubMed ID: 18020248
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunotherapy in inflammatory bowel disease.
    Ahluwalia JP
    Med Clin North Am; 2012 May; 96(3):525-44, x. PubMed ID: 22703854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
    Verma HD; Scherl EJ; Jacob VE; Bosworth BP
    J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?
    Scott DL; Cope A
    Ann Rheum Dis; 2009 Jun; 68(6):767-9. PubMed ID: 19435722
    [No Abstract]   [Full Text] [Related]  

  • 30. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
    Leung Y; Hanauer SB
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S202-8. PubMed ID: 20117343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Inflammatory bowel diseases--new therapeutic options].
    Herrlinger K; Stange EF
    Med Klin (Munich); 2008 Feb; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent developments in the treatment of inflammatory bowel disease.
    Rietdijk ST; D'Haens GR
    J Dig Dis; 2013 Jun; 14(6):282-7. PubMed ID: 23419117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Certolizumab pegol].
    Delgado Frías E; Díaz González JF
    Reumatol Clin; 2011 Mar; 6S3():S7-11. PubMed ID: 21794764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
    Aletaha D
    BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233
    [No Abstract]   [Full Text] [Related]  

  • 35. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.
    Shelton E; Chaudrey K; Sauk J; Khalili H; Masia R; Nguyen DD; Yajnik V; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2015 May; 41(10):972-9. PubMed ID: 25756190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
    Lazebnik LB; Kniazev OV
    Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
    [No Abstract]   [Full Text] [Related]  

  • 38. Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block.
    Mittal M; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2010; 76(6):602-8; quiz 609. PubMed ID: 21079302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.
    Rubin DT; Uluscu O; Sederman R
    Inflamm Bowel Dis; 2012 Dec; 18(12):2225-31. PubMed ID: 22359399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.